Literature DB >> 12455906

Adverse events associated with 17D-derived yellow fever vaccination--United States, 2001-2002.

.   

Abstract

In June 2001, seven cases of yellow fever vaccine-associated viscerotropic disease (YEL-AVD) (previously called multiple organ system failure) in recipients of 17D-derived yellow fever vaccine (YEL) were reported to the Advisory Committee on Immunization Practices (ACIP). ACIP reviewed the cases, recommended enhanced surveillance for adverse events, and updated the ACIP statement on YEL. This report summarizes the preliminary surveillance findings, including two new suspected cases of YEL-AVD and four suspected cases of YEL-associated neurotropic disease (YEL-AND) (previously called postvaccinal encephalitis). Although YEL remains essential for travelers to areas in which yellow fever (YF) is endemic (Figure), these findings underscore the need for continued enhanced surveillance and timely clinical assessment of YEL-associated disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12455906

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  21 in total

1.  Yellow Fever Immunizations: Indications and Risks.

Authors:  Mary E. Wilson; Lin H. Chen; Elizabeth D. Barnett
Journal:  Curr Infect Dis Rep       Date:  2004-02       Impact factor: 3.725

2.  A case of yellow fever vaccine-associated viscerotropic disease in Ecuador.

Authors:  Richard W Douce; Diana Freire; Betzabe Tello; Gavino A Vásquez
Journal:  Am J Trop Med Hyg       Date:  2010-04       Impact factor: 2.345

3.  Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization?

Authors:  M A Martins; M L Silva; A P V Marciano; V Peruhype-Magalhães; S M Eloi-Santos; j G L Ribeiro; R Correa-Oliveira; A Homma; E G Kroon; A Teixeira-Carvalho; O A Martins-Filho
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

Review 4.  [Vaccination and multiple sclerosis].

Authors:  M Löbermann; A Winkelmann; E C Reisinger; U K Zettl
Journal:  Nervenarzt       Date:  2010-02       Impact factor: 1.214

5.  Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on yellow fever virus infection in a hamster model.

Authors:  Justin G Julander; John D Morrey; Lawrence M Blatt; Kristiina Shafer; Robert W Sidwell
Journal:  Antiviral Res       Date:  2006-09-22       Impact factor: 5.970

Review 6.  Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner.

Authors:  Celia Oreja-Guevara; Heinz Wiendl; Bernd C Kieseier; Laura Airas
Journal:  Ther Adv Neurol Disord       Date:  2014-03       Impact factor: 6.570

7.  Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.

Authors:  Justin G Julander; Kristiina Shafer; Donald F Smee; John D Morrey; Yousuke Furuta
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

8.  A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys.

Authors:  F Guirakhoo; Z Zhang; G Myers; B W Johnson; K Pugachev; R Nichols; N Brown; I Levenbook; K Draper; S Cyrek; J Lang; C Fournier; B Barrere; S Delagrave; T P Monath
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

9.  Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates.

Authors:  F Guirakhoo; K Pugachev; Z Zhang; G Myers; I Levenbook; K Draper; J Lang; S Ocran; F Mitchell; M Parsons; N Brown; S Brandler; C Fournier; B Barrere; F Rizvi; A Travassos; R Nichols; D Trent; T Monath
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

10.  A randomized, double-blind, controlled trial of the 17D yellow fever virus vaccine given in combination with immune globulin or placebo: comparative viremia and immunogenicity.

Authors:  Srilatha Edupuganti; Rachel B Eidex; Harry Keyserling; Rama S Akondy; Robert Lanciotti; Walter Orenstein; Carlos del Rio; Yi Pan; Troy Querec; Harvey Lipman; Alan Barrett; Rafi Ahmed; Dirk Teuwen; Martin Cetron; Mark J Mulligan
Journal:  Am J Trop Med Hyg       Date:  2012-12-03       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.